Table of Contents
ISRN Pulmonology
Volume 2011, Article ID 423571, 4 pages
Research Article

Complement C3 Genotype Variants and Risk of Lung Cancer Mortality

1The Copenhagen Male Study, Epidemiological Research Unit, Department of Occupational and Environmental Medicine, Bispebjerg University Hospital, Bispebjerg Bakke 23, 2400 Copenhagen NV, Denmark
2Research Centre for Prevention and Health, Glostrup University Hospital, 2600 Copenhagen, Denmark

Received 3 June 2011; Accepted 7 July 2011

Academic Editor: C. Brambilla

Copyright © 2011 Poul Suadicani et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Inflammation and genetic susceptibility influence the risk of lung cancer. During recent years, the role of complement as a part of the humoral response has advanced from being considered complementary to being regarded as a central element in innate immunity. C3 complement allotypes F and S have been associated with a number of inflammatory diseases. The C3F allele frequency is approximately 20% in Caucasian populations and the C3S approximately 80%, resulting in the three predominant genotypes FF (4%), FS (32%), and SS (64%). To our knowledge, no studies have investigated if different C3 allotypes or genotypes predict the risk of lung cancer. We tested in a long-term followup of 3,197 men aged 53 to 74 years the hypothesis that risk of lung cancer would depend on C3 complement genotypes. During 16 years, 160 subjects (5.0%) died from lung cancer, 68 men (6.1%) among complement C3 genotypes FS/FF, and 92 men (4.4%) among genotype SS; age-adjusted hazard ratio with 95%CI (HR) was 1.42 (1.04–1.94) and strongest, 2.71 (1.34–5.45), among the oldest fifth. C3 complement genotype variants were significantly associated with lung cancer mortality.